Stephan Mumenthaler – Director General, scienceindustries, Switzerland

scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how the country’s evolving relationship with the EU stands to impact the industry, and Switzerland’s progress on the road to full digitalisation and Pharma 2.0  
What our members want is a good and stable relationship with their most important trading partners, top among which is the EU
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report